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Dear friends and colleagues,
In our offices in South Africa and the United States hang placards bearing an important daily reminder of
IPM’s mission: to put safe and effective microbicides in the hands of women. Every day, we face the sobering fact that women and girls remain at high risk of HIV infection. This year, we are excited to be preparing
for the possibility that the monthly dapivirine ring could soon offer women a new way to protect their
health.
The continuing high rates of new HIV infections in women underscore the importance of acting quickly
should the dapivirine ring prove effective. With efficacy results from the two parallel Phase III trials of the
ring expected by early 2016, IPM has intensified its regulatory and access planning. By preparing now, we
can maximize the ring’s potential public health impact.
During a year when the global community is setting goals for improving women’s health and sustainable
development, the HIV prevention research field is at a critical juncture. As the recent FACTS 001 results
highlighted, women—especially young women in sub-Saharan Africa—need HIV prevention methods they
can and will use. Research to develop new products must continue alongside efforts to better understand
the role of oral pre-exposure prophylaxis, or PrEP, as an HIV prevention tool for women.
In addition to the dapivirine ring, IPM is advancing a variety of promising technologies that would expand
women’s prevention options. This year, we will initiate a first-in-human clinical trial of a vaginal tablet
containing a new antiretroviral (ARV) drug, DS003, which will be developed further as a long-acting
vaginal ring. A Phase I trial of IPM’s 90-day dapivirine-contraceptive ring designed to simultaneously
prevent HIV and unintended pregnancy is expected to begin in early 2016. We are also supporting several
trials of different vaginal and rectal formulations of various ARVs.
From the time IPM was founded in 2002, we have marshalled scientific know-how, creative partnerships
and resources to develop lifesaving tools for women’s sexual and reproductive health. With the support
and relentless commitment of countless clinical trial volunteers, donors and partners, that reality is coming
into sharper focus.

Dr. Zeda F. Rosenberg

Dr. James McIntyre

Every day,

nearly 2,500 women worldwide are infected with HIV. In sub-Saharan Africa,
young women are at least twice as likely to be infected as young men. Moreover, 225 million women worldwide have an unmet need for family planning. Women critically need a range of new prevention tools that
match their individual needs and fit into the context of their lives.
Expanding and sustaining a diverse product pipeline is vital to helping prevent HIV over
time and supporting women’s sexual and reproductive health. IPM is responding with
a robust, cutting-edge pipeline of long-acting female-initiated products.

Dapivirine Ring
Designed to:

Protect women against HIV

Formulation:

Self-inserted flexible silicone matrix vaginal ring designed for 		

		 one-month protection, with a three-month ring in development
Active ingredient:
Mechanism of action:

Dapivirine (ARV)
Non-nucleoside reverse transcriptase inhibitor (NNRTI) 		

		 that blocks HIV’s ability to replicate itself in healthy cells

A Brief History of the Ring
From the beginning, IPM focused on identifying potent ARVs

First Efficacy Trials of a
Long-Acting Microbicide

that could be harnessed for safe and easy-to-use microbicide

After advancing the dapivirine ring from an idea to Phase III

products. In 2004, IPM was approached by Janssen Sciences

trials in just seven years, IPM launched the Dapivirine Ring

Ireland UC, a Janssen pharmaceutical company of Johnson &

Licensure Program in 2012. Because regulatory authorities

Johnson, and negotiated a royalty-free license to develop the

usually require data from at least two large-scale efficacy

ARV drug dapivirine as a topical microbicide for women’s HIV

trials along with supporting studies to approve a product, IPM

prevention in developing countries. This license expanded to

designed a program to supply the necessary data comprehen-

an exclusive worldwide rights agreement in 2014.

sively and efficiently.

From 2004 to 2010, IPM evaluated dapivirine in an extensive

Given the ring’s promise, the US National Institutes of

program of preclinical assessments and clinical studies. In

Health-funded Microbicide Trials Network (MTN) joined the

2010, we prioritized a ring formulation that would provide

licensure program as a clinical trial partner to keep the time

discreet, long-acting protection to women. Building on early

line to regulatory approval as short as possible. This program

prototypes, IPM developed the current monthly dapivirine

includes two parallel Phase III trials: The Ring Study, led by

ring in collaboration with Queens University Belfast (QUB).

IPM, and the ASPIRE study, led by MTN. Both studies reached

From 2009 to 2014, IPM completed a series of safety and

full enrollment in 2014, with more than 4,500 women enrolled

pharmacokinetics studies of the ring, as well as acceptability

across Malawi, South Africa, Uganda and Zimbabwe. The

research showing that vaginal rings were highly acceptable to

ASPIRE study completed participant follow-up in June 2015,

women and their male partners, and that women are willing

while The Ring Study, which was designed to collect long-

to use a ring if it prevents HIV.

term safety data, continues until late 2016. Final results from
ASPIRE as well as efficacy and preliminary safety results from
The Ring Study are expected by early 2016.
The Promise of Prevention for Women
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Focusing on retention and adherence: IPM continand communities to keep them engaged in the trials and

On the Regulatory Pathway:
The Dapivirine Dossier

encourage product adherence through outreach events

IPM continues to consult with the European Med-

and educational activities. In addition, The Ring Study uses

icines Agency, US Food and Drug Administration,

objective adherence measures such as assessing the amount

South African Medicines Control Council and addi-

of dapivirine remaining in used rings as well as drug levels

tional African regulatory authorities to ensure we

in plasma and vaginal fluid samples, all in addition to data

meet regulatory data requirements. These data are

from interviews and questionnaires.

being organized into a global dossier on the dapivir-

Supporting studies: A package of smaller studies

ine ring containing information on everything from

ues to work actively with research center staff, participants

required for regulatory approval also moved ahead in 2014.
IPM completed studies on dapivirine’s interaction with a
drug commonly used to treat vaginal yeast infections, the
ring’s compatibility with female and male condoms, and

its ingredients to findings from nearly 250 studies of
dapivirine over 13 years. Compiling this master electronic file will allow us to quickly adapt the dossier for
future country-specific regulatory submissions.

extended use of the ring. In addition, IPM initiated a study of
sociobehavioral factors of adherence. In collaboration with
MTN, we initiated studies on safety in adolescent females

Roadmap to Access

and safety in women over 45. IPM planned for a study on the

Introducing and scaling up a new product requires a deep

effects of menses and tampon use on the ring, now under

network of resources and collaborations. In 2014, IPM drafted

way, as well as a second drug interaction study.

a comprehensive plan to facilitate affordable and sustainable

Preparing for an
Effective Microbicide
To get an effective ring into women’s hands as quickly as
possible, IPM planned for potential licensure and access
from the ring’s initial development and throughout the
research process. As the dapivirine ring’s developer and
regulatory sponsor, IPM engages partners to lay the groundwork for the ring’s regulatory submission, manufacturing,
distribution, financing and access.

After efficacy: open-label studies: Should the ring

access to a future dapivirine ring. As part of this plan, we
selected QPharma, which completed ring manufacturing for
the licensure program in 2014, as our launch manufacturing
partner. IPM also planned a suite of studies and activities now
under way to drive the ring’s distribution, financing and use,
pending efficacy results. These include a cost-effectiveness
study, strategies to ensure adequate funding and political
support, and supply and distribution partner selection. IPM
is also working on advocacy, awareness-raising and training
activities for groups key to successful product introduction —
from women to civil society organizations to health workers
and many others.

prove effective, women who participated in the Phase III

Recognizing that product access strategies will need to be tai-

studies would be given access to the active ring. All partici-

lored to specific regions, IPM is meeting with stakeholders in

pants who are still enrolled in The Ring Study would receive

countries where the ring would be introduced. These partner-

active rings for the remainder of their participation. In addi-

ships expand our understanding of market dynamics, public

tion, IPM and MTN would each initiate a Phase IIIb follow-on

policy, and the cultural, financial and other factors that affect

study to provide all previous Ring Study and ASPIRE partic-

women’s willingness and ability to access a future ring.

ipants with the active ring for at least one year while the
product is undergoing review by regulatory authorities
for broad distribution. The Phase IIIb studies would also
collect additional safety and adherence data.

A staff member
processes samples
for The Ring Study
at the Desmond Tutu
HIV Foundation in
Masiphumulele,
South Africa.
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Staff at Maternal, Adolescent and Child Health (MatCH) in Kwazulu-Natal,
South Africa, celebrate The Ring Study reaching full enrollment in 2014.

A staff member organizes
blood samples for The Ring
Study at the Uganda Virus
Research Institute in
Masaka, Uganda.

Dapivirine-Contraceptive Ring

The dual threats to women’s health from HIV/AIDS and

IPM is partnering with MTN to conduct a Phase I pharma-

complications due to unintended pregnancy are not a

cokinetics and safety trial of the three-month MPT ring in

burden women should have to bear. Under a USAID grant

the United States to begin in early 2016. As the regulatory

through PEPFAR, IPM is adapting its vaginal ring to provide

sponsor for this first-in-human trial, IPM initiated plans to

women with a self-initiated three-month multipurpose pre-

ensure sufficient drug supplies for the trial, and selected

vention technology (MPT) designed to prevent both HIV and

QPharma to manufacture Good Manufacturing Prac-

unintended pregnancy.

tice-quality rings.

Expanding Women’s
Sexual and Reproductive
Health Options

MPT collaborations: IPM is also providing placebo
vaginal rings for the Bill & Melinda Gates Foundation-funded TRIO study assessing the acceptability of ring, oral tablet
and injectable MPT formulations among South African

IPM’s MPT ring combines dapivirine, an ARV, and levo-

and Kenyan women. Led by RTI International, the study is

norgestrel, a contraceptive hormone. In 2014, after evaluat-

expected to begin in 2015.

ing multiple ring designs and materials, IPM expanded the
MPT ring’s target length of action from two months to three
months, and collaborated with QUB to develop a flexible
silicone matrix prototype.

DS003 Tablet and Ring

To outsmart the ever-evolving HIV virus over the long term,

In 2014, IPM initiated preclinical toxicology and pharmaco-

IPM is exploring new drugs that use alternative mechanisms

kinetics studies on DS003. Based on encouraging results

of action. A gp120 binder, DS003 is a promising ARV can-

of these and previous preclinical tests, IPM plans to lead a

didate because it directly targets HIV and acts early in the

Phase I safety and tolerability trial of the DS003 tablet in late

virus’s lifecycle to block HIV’s ability to enter healthy cells.

2015. The findings from that first-in-human trial will be used

IPM is studying several DS003 formulations for women,
including a single-use vaginal tablet (in collaboration with

to inform development of a long-acting vaginal ring that
would combine DS003 with another ARV.

the University of South Australia) and a three-month vaginal

IPM negotiated with Bristol-Myers Squibb for a royalty-free

ring (in collaboration with QUB).

worldwide license to DS003 in 2005.

The Promise of Prevention for Women
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“It’s more important than ever that alternative methods of
HIV prevention for women are developed.“
– Naledi Pandor, South African Minister of Science and Technology

Controlled-release delivery system being
explored for dapivirine-maraviroc ring.
Photo courtesy of Oak Crest Institute of
Science.

Dapivirine-Maraviroc Ring

Combination ARV products may offer greater protection

optimize the formulation to target higher release levels of

against HIV than a single drug alone. IPM’s one-month

maraviroc, IPM is partnering with the Oak Crest Institute of

combination vaginal ring leverages two potent ARVs with

Science to explore its controlled-release ring delivery

different mechanisms of action: dapivirine, an NNRTI, and

system that uses embedded ARV-loaded pods to release

maraviroc, a CCR5 receptor antagonist that blocks HIV’s

the active drugs.

ability to enter healthy cells. The first combination microbicide to enter clinical trials for HIV prevention, the ring was
found in 2014 to be safe, well-tolerated and acceptable
in a Phase I trial conducted in partnership with MTN. To

IPM began developing maraviroc, an ARV currently used
for oral HIV treatment, as a microbicide in 2008 through a
royalty-free licensing agreement held by ViiV Healthcare.

Dapivirine-Darunavir Ring and Gel
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IPM is investigating different formulations of darunavir, a

Following preclinical toxicology studies of a daily

protease inhibitor that blocks HIV’s ability to produce via-

dapivirine-darunavir vaginal gel led by CHAARM in 2014,

ble virus, and is currently used orally to treat HIV. Working

IPM supplied clinical materials for a Phase I trial initiated

with the European Commission-funded CHAARM project,

in 2015 at the University of York in England. The safety and

preclinical studies of the pharmacokinetics and efficacy

pharmacokinetics study is evaluating a single dose and

of a one-month dapivirine-darunavir vaginal ring were

daily use of the combination gel, with a darunavir-only gel

completed in 2014.

arm for comparison.
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Other Pipeline Products
IPM is collaborating with research partners on other promising
microbicide products, including:

• Dapivirine vaginal film. In 2014, Johns Hopkins University
completed a Phase I trial of the single-use dapivirine vaginal
film. Developed in collaboration with the NIH-funded Ma-

Engaging stakeholders to plan for access: In 2014, IPM
undertook an educational outreach campaign to raise awareness
of microbicides generally and the ring specifically in Kenya, Malawi and Zimbabwe. Health workers advised on the information
they would need to recommend a future ring and on education
programs. Policymakers shared ideas on stakeholders and initiatives needed to build support for the ring.

gee-Womens Research Institute FAME program, the film was
found to produce encouraging dapivirine levels in cervical
tissue. With IPM’s support, the FAME program is also investigating combination films, including a dapivirine-DS003 vaginal
film.

• Maraviroc-based rectal gel. In 2014, IPM oversaw the

A staff member of Ndlovu
Care Group in Limpopo,
South Africa, describes the ring
during an educational session
to engage men in HIV
prevention research.

production of clinical supplies and received approval to begin
a Phase I trial of maraviroc-based gel. The CHARM-03 trial was
launched in 2015 by the NIH-funded CHARM program at the
University of Pittsburgh, comparing maraviroc in gels used
rectally and vaginally as well as in oral pills in women and men.

• Dapivirine rectal gel. IPM is partnering with MTN for a
Phase I trial in 2015 to evaluate the safety and pharmacokinetics
of dapivirine gel used rectally by women and men. A second
Phase I trial is planned for 2016 in conjunction with MTN and
product developer CONRAD.

Building Awareness

Tools for Health Workers and Policymakers
IPM incorporated findings from its qualitative study of health
workers’ microbicide knowledge and perceptions into a suite
of new materials to familiarize health workers and policymakers with the ring and how it is used. These materials will
be used for future educational campaigns during product
roll-out, should the ring prove effective.

IPM continues to engage trial communities, civil society and
government partners through community events, briefings and
information-sharing to support health and research literacy, and

Advocating for a healthy future: The well-being of women

to gather feedback that informs our research and access plan-

and girls must be prioritized to encourage sustainable growth.

ning. In 2014, outreach activities continued in collaboration with

In 2014, IPM and its partners began advocating for the inclusion

advocacy organizations such as the Southern African AIDS Trust

of HIV/AIDS prevention and sexual and reproductive health

in Malawi and Zimbabwe, the Kenya Medical Women’s Associ-

priorities in the Sustainable Development Goals, which outline

ation, AIDS-Fondet in Denmark, Sex og Politikk in Norway and

a global vision for the next 15 years and are now being finalized

Aids Fonds in the Netherlands.

by the United Nations. IPM’s pipeline is designed to empower

Civil society consultations: IPM, together with MTN and

women to protect themselves, slow the

the HIV prevention advocacy organization AVAC, held a series
of consultations in 2014 in Malawi, South Africa, Uganda and
Zimbabwe with nearly 150 civil society representatives to solicit
feedback on the preliminary designs for future open-label
Phase IIIb studies of the dapivirine ring.
This input informed the study protocols
submitted to research ethics committees in late 2014. IPM will build on these
consultations while planning for product
roll-out.
In August 2014, IPM, MTN and AVAC met
with civil society representatives in Malawi
as part of a series of consultations in the four
countries where the Phase III dapivirine ring
trials are taking place.

HIV epidemic and support
healthy, productive societies.

IPM co-authored or supported 30 oral and
poster presentations at the inaugural HIV
R4P Conference, focused on biomedical
HIV prevention research. Senior IPM staff
also co-chaired two oral abstract sessions
at the Cape Town conference.

IPM’s CEO Dr. Zeda Rosenberg highlighted
women’s HIV prevention needs as part of FHI360’s
video interview series for the 20th International
AIDS Conference in Melbourne, Australia.

IPM’s Technical Lead
of Analytical Sciences
Dr. Stephen Ampofo

IPM’s Chief
Medical Officer
Dr. Annalene Nel

IPM’s Senior Director of Product
Development Dr. Jeremy Nuttall

Leading with science: IPM’s work was presented

IPM published research on the dapivirine ring, gel and

at many major scientific conferences in 2014. Highlights

film in journals such as AIDS, the Journal of AIDS &

include results from Phase I studies of the dapivirine film

Clinical Research, AIDS Research and Human Retrovi-

and dapivirine-maraviroc ring at the Conference on Retro-

ruses, and Molecular Pharmaceutics. IPM also published

viruses and Opportunistic Infections in Boston, and dapi-

articles on sociobehavioral research in the Journal of the

virine ring and MPT ring research at the HIV Research for

International AIDS Society and on MPTs in a special sup-

Prevention (R4P) Conference in Cape Town, South Africa.

plement to BJOG: An International Journal of Obstetrics
& Gynaecology.

IPM Donors
Current Donors
Bill & Melinda Gates Foundation
Flanders Department of Foreign
Affairs
Irish Aid, Department of Foreign
Affairs

Ministry of Foreign Affairs and
Cooperation, Spain
Ministry of Foreign Affairs, France
OPEC Fund for International
Development, the development
finance institution of OPEC
Member States
Rockefeller Foundation

Ministry of Foreign Affairs of
Denmark

Swedish International Development
Agency

Ministry of Foreign Affairs of
the Netherlands

United Nations Population Fund

Norwegian Agency for
Development Cooperation,
Norwegian Ministry of Foreign
Affairs

Board
of Directors

United Kingdom Department for
International Development
United States Agency for
International Development through
the United States President’s
Emergency Plan for AIDS Relief

Previous Donors
Ackerman Family Foundation
Belgian Development Cooperation
Canadian International
Development Agency
European Commission
Federal Ministry for Economic
Cooperation and Development,
Germany
M•A•C AIDS Fund
Magee-Womens Research Institute
and Foundation
Ministry for Foreign Affairs,
Sweden

World Bank

Ndola Prata, MD, MSc
University of California, Berkeley
School of Public Health,
United States
Zeda F. Rosenberg, ScD
IPM, United States
Michael Stevens
ENTHUSE Charitable Trust,
United Kingdom
Heidemarie Wieczorek-Zeul
Former Member of Parliament,
German Bundestag, Germany

Scientific
Advisory
Board

Deenan Pillay, MD
University of Kwazulu-Natal,
South Africa
Doug Taylor, PhD
FHI 360, United States
Jim A. Turpin, PhD
National Institute of Allergy and
Infectious Diseases, National
Institutes of Health, United States
Lut Van Damme, PhD
Bill & Melinda Gates Foundation,
United States
Jens Van Roey, MD
Janssen Infectious Diseases Diagnostics BBVA, Belgium
Robin Wood, PhD
Desmond Tutu HIV Centre,
South Africa

James McIntyre, MBChB, Chair
Anova Health Institute, South Africa

Robin Shattock, PhD, Chair
Imperial College London, United
Kingdom

Ayo Ajayi, MD, MPH
Bill & Melinda Gates Foundation,
Ethiopia

Michael Chirenje, MD
University of Zimbabwe, Zimbabwe

IPM
Leadership

David R. Friend, PhD
Evofem, United States

Zeda F. Rosenberg, ScD
Chief Executive Officer

Georgina Caswell, MA
International HIV/AIDS Alliance,
South Africa

Sharon Hillier, PhD
Magee-Womens Hospital,
University of Pittsburgh School
of Medicine, United States

Lynn Bodarky, MBA
Executive Vice President,
Global Product Access

Tamar Howson, MS, MBA
Independent Consultant,
United States

Ruth B. Merkatz, PhD, RN, FAAN
Population Council,
United States

Brid Devlin, PhD
Executive Vice President,
Product Development

Maureen Lewis, PhD
Georgetown University,
United States

Thomas Moench, MD
ReProtect, Inc., United States

Mike Goldrich, MBA
Chief Financial Officer

Bruce Burlington, MD
Independent Consultant,
United States

Florence W. Manguyu, M.Med,
MBChB
Aga Khan University Hospital; IAVI,
Kenya
David Nicholson, PhD
Allergan, United States

Edith Nakku-Joloba, PhD
Makerere University School of
Public Health, Uganda
Derek Newall, PhD
GlaxoSmithKline, United Kingdom

Prem K. Narang, PhD, FCP
Executive Vice President,
Regulatory Affairs
Annalene Nel, MD, PhD
Executive Vice President,
Chief Medical Officer, Clinical
Programs

2014 Financial Considerations
IPM’s cash, cash equivalents and short-term investments
as of December 31, 2014 totaled USD 23.7 million. During
2014, IPM continued to increase clinical research center
expenditures in Africa in support of The Ring Study, one
of two parallel Phase III clinical trials of the dapivirine ring.
Seven research centers are participating in the ongoing
clinical study. Significant expenditures for chemistry, manufacturing and control activities as well as a robust clinical
infrastructure support this pivotal trial. In addition, IPM
increased its activities in FY 2014 to prepare for access to
a potentially effective ring.
In 2014, IPM received approximately USD 22 million from
eight donors, including significant awards from USAID,
DFID, the Ministry of Foreign Affairs of the Netherlands,
Irish Aid and the Bill & Melinda Gates Foundation. We also
continued to receive important support from our
other donors. IPM is in compliance with all financial
reporting requirements from all domestic, international
government and private donors, and has received
unqualified, or clean, opinions on all audits in both our US
and South Africa offices.

With new funding received in 2014, IPM also advanced its
product pipeline, an integral component of the organization’s strategy beyond the Dapivirine Ring Licensure Program. In consultation with its Scientific Advisory Board,
IPM will continue to apply a highly disciplined approach to
product prioritization that advances only the most promising self-initiated HIV prevention tools and other sexual
and reproductive health technologies for women.
IPM’s Board of Directors, management team and staff
are committed to efficiently and effectively delivering on
our mission to advance new methods to protect women
around the world from HIV infection. Because sustained
donor funding for IPM’s success is essential to achieving
our mission, we continue to advocate for increased funds
from existing donors and pursue new sources of support
to achieve our goals.

		

EXPENSES BY DEPARTMENT

ASSETS
Cash and cash equivalents

Institutional
Operating
17%

Clinical
Programs
40%

$17,211,932

Investments, at market

$6,444,218

Accounts receivable

$3,253,478

Prepaid expenses and other current assets

$1,160,959

Property and equipment, net
Total Assets

$802,435
$28,873,022

LIABILITIES AND NET ASSETS
Liabilities

Access 3%
External
Relations
7%
Regulatory
& Quality
Assurance
8%

DEC. 31, 2014

Accounts payable and accrued expenses
Product
Development
26%

$2,308,972

Grant advances and deferred revenue

$11,778,472

Total Liabilities

$14,087,444

Net Assets — unrestricted

$14,785,578

“We need to fast track female-controlled HIV prevention methods.“
–Michel Sidibé, Executive Director, UNAIDS

Learn more about how to promote women’s health worldwide
and save millions of lives at www.IPMglobal.org
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